RT Journal Article SR Electronic T1 Somatic mutations in Parkinson disease are enriched in synaptic and neuronal processes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.14.20190538 DO 10.1101/2020.09.14.20190538 A1 Irene Lobon A1 Manuel Solís-Moruno A1 David Juan A1 Ashraf Muhaisen A1 Federico Abascal A1 Paula Esteller-Cucala A1 Raquel García-Pérez A1 Maria Josep Martí A1 Eduardo Tolosa A1 Jesús Ávila A1 Raheleh Rahbari A1 Ferran Casals A1 Tomas Marques-Bonet A1 Eduardo Soriano YR 2020 UL http://medrxiv.org/content/early/2020/09/15/2020.09.14.20190538.abstract AB The role of somatic mutations in complex diseases, including neurodevelopmental and neurodegenerative disorders, is becoming increasingly clear. To explore their relevance in sporadic Parkinson disease, we performed whole-exome sequencing in blood and four brain regions of ten patients. We identified 59 candidate somatic single nucleotide variants (sSNVs) through sensitive calling and extensive filtering. We validated 27 of them with amplicon-based deep sequencing, with a 70% validation rate for the highest-confidence variants. Most of the sSNVs were exclusively called in blood but were also found in the brain tissues with the ultra-deep amplicon sequencing, demonstrating the strength of multi-tissue sampling designs. We could confirm between 0 and 6 sSNVs per patient and generally those with a shorter lifespan carried more variants. Remarkably, the validated sSNVs are enriched in genes with synaptic functions that are co-expressed with genes previously associated with Parkinson disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMINECO (Ministerio de Economia y Competitividad) grants SAF2016-76340-R to E.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were acquired after death with informed consent from Parkinson patients at Hospital Clinic Barcelona, Spain. Ethical approval for the study was gained from the hospital's Clinical Research Ethics Committee (Reference HCB/2016/0259) in accordance with LIB 14/2007 and RD 1716/2011.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available on request and will be deposited in a public repository. Methods including COSMOS are available in GitHub https://github.com/ilobon/COSMOS